HR 5582
115th Congress
House
Health
Congressional oversight
Drug therapy
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Government studies and investigations
Health care costs and insurance
Health care coverage and access
Health promotion and preventive care
Medicare
Prescription drugs
Abuse Deterrent Access Act of 2018
Introduced: April 23, 2018
Introduced by:
Carter, Earl L. "Buddy"
Republican
· Georgia
See on congress.gov
Everywhere this bill has been
15 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 13, 2018
Received in the Senate and Read twice and referred to the Committee on Finance.
Jun 12, 2018
Motion to reconsider laid on the table Agreed to without objection.
Jun 12, 2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5061)
Jun 12, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5061)
Jun 12, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5582.
Jun 12, 2018
Considered under suspension of the rules. (consideration: CR H5061-5063)
Jun 12, 2018
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Jun 8, 2018
Placed on the Union Calendar, Calendar No. 556.
Jun 8, 2018
Committee on Ways and Means discharged.
Jun 8, 2018
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-721, Part I.
May 9, 2018
Ordered to be Reported (Amended) by Voice Vote.
May 9, 2018
Committee Consideration and Mark-up Session Held.
May 1, 2018
Referred to the Subcommittee on Health.
Apr 23, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 23, 2018
Introduced in House
Plain-English summary
Abuse Deterrent Access Act of 2018
(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in a prescription drug plan under Medicare or Medicare Advantage (MA). The report must account for any barriers preventing enrollees from accessing such formulations under Medicare or MA.
What's happening now
Received in the Senate and Read twice and referred to the Committee on Finance.
Committees of jurisdiction
4
Cosponsors
1